Narcan maker Emergent axes top R&D post in sweeping restructuring
Emergent BioSolutions is eliminating the role of chief medical officer and head of R&D in a sweeping restructuring that leaves the Narcan maker without a dedicated C-suite R&D leader.
Emergent BioSolutions
American multinational specialty biopharmaceutical company and global biodefense contractor; develops and manufactures medical countermeasures for biological threats and infectious diseases, including NARCAN nasal spray and anthrax vaccines. In August 2026 it eliminated the chief medical officer / head of R&D role in a sweeping restructuring.
Company Info
Sector:Biodefense / Specialty Biopharmaceuticals
Headquarters:Gaithersburg, Maryland, USA
Founded:1998
Website:www.emergentbiosolutions.com/
Upcoming Milestones & Key Dates
2026-08-05
Earnings
Q2 2026 results; multi-year transformation plan update
Clinical Development Pipeline
NARCAN (naloxone) nasal spray
Target: Opioid receptor antagonistBioThrax
Target: Anthrax vaccineVIGIV
Target: Vaccinia immune globulinWorkforce & Restructuring Tracker
View Industry Layoff Tracker →$40M restructuring & R&D cutsConfirmed
Emergent BioSolutions eliminated its Chief Medical Officer / Head of R&D post and initiated a $40M cost-saving workforce restructuring following a $191.3M non-cash impairment on its NARCAN naloxone franchise.
Recent News
Leadership Team
Joseph C. Papa
President and Chief Executive Officer (since Feb 2024)